A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 116 participants.
Also called NCT05843162
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 116 participants
- Registry
-
NCT05843162
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT05843162. Randomized; no masking; primary purpose treatment. Start 2023-06-01 (anticipated); primary completion 2023-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Clinical Trial to Evaluate the Blood Pressure Control of Telmisartan or Losartan in Essential Hypertensive Patients With Metabolic Syndrome
- Acronym
- PRISTINE
- Condition
- Essential Hypertension
- Condition
- Metabolic Syndrome
- Intervention (Drug)
- Telmisartan
- Intervention (Drug)
- Losartan
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct05843162- Content hash
34c9cc35a6049ce0b422b3b46b6b6945be74d3057544f77ed9c7fff841c0855b